Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06049082 · ClinicalTrials.gov registry record · Phase 1
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
A Phase 1 study of Alpha-1 Antitrypsin Deficiency, sponsored by Krystal Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 3
- Study locations
NCT06049082 is a Phase 1 study of Alpha-1 Antitrypsin Deficiency that is actively recruiting participants, run by Krystal Biotech. The registered enrollment target is 15 participants, below the 3,077-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06049082, a Phase 1 study of Alpha-1 Antitrypsin Deficiency, is actively recruiting participants, sponsored by Krystal Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 3
- Study locations
Study Summary
The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency (AATD) via nebulization. This study is designed to evaluate safety and pharmacodynamics of KB408 in adults with AATD with a PI\*ZZ or PI\*ZNull genotype. Three planned dose levels of KB408 will be evaluated in single dose escalation cohorts. Repeat dosing will be evaluated at the mid dose level. Subjects taking intravenous AAT augmentation therapy are not required to wash out from IV AAT in the low and mid dose cohorts. In the repeat dose and the high dose cohorts, subjects must wash out from IV AAT for at least 10 days, as applicable.
Conditions Studied
Interventions
- DRUG KB408 (Nebulization)
Study Locations (3)
Florida
- University of Florida, Gainesville - Gainesville
South Carolina
- Medical University of South Carolina - Charleston
Texas
- Renovatio Clinical - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06049082
The ClinicalTrials.gov registry entry for NCT06049082 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,077-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (100% lower). The listed sponsor is Krystal Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 1 intervention - of which KB408 (Nebulization) is the first listed.
NCT06049082 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, South Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT06049082 about?
NCT06049082 is a clinical study titled "A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency". The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency (AATD) via nebulization. This study is designed to eva...
What is the current status of trial NCT06049082?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-02-15. Estimated completion is 2026-12.
What conditions does trial NCT06049082 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.
What interventions are being tested in trial NCT06049082?
The interventions under investigation include: KB408 (Nebulization) (DRUG).
Who is sponsoring clinical trial NCT06049082?
This trial is sponsored by Krystal Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06049082 being conducted?
This trial has 3 study locations across Florida, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
RECRUITING · Phase 1
-
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
RECRUITING · Phase 1
-
A Phase 1, First-in-human Study of VX-668
COMPLETED · Phase 1
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.